Position paper on CDK4/6 inhibitors in early breast cancer

被引：1

作者：

Gnant, Michael ^{[1
]}

Singer, Christian F. ^{[2
]}

Rinnerthaler, Gabriel ^{[3
]}

Pfeiler, Georg ^{[2
]}

Egle, Daniel ^{[4
]}

Balic, Marija ^{[5
]}

Bartsch, Rupert ^{[6
]}

机构：

[1] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

[2] Med Univ Vienna, Dept Gynecol & Gynecol Oncol, Vienna, Austria

[3] Paracelsus Med Univ Salzburg, Oncol Ctr, Dept Internal Med 3, Haematol Med Oncol Haemostaseol Infectiol & Rheuma, A-5020 Salzburg, Austria

[4] Med Univ Innsbruck, Breast Canc Ctr Tirol, Dept Gynecol, Innsbruck, Austria

[5] Med Univ Graz, Dept Internal Med, Div Clin Oncol, Graz, Austria

[6] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria

来源：

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷 / 02期

关键词：

Breast cancer; Adjuvant therapy; Cell cycle inhibitors; CDK4; 6; inhibitors; RIBOCICLIB PLUS LETROZOLE; THYMIDINE KINASE-ACTIVITY; ENDOCRINE THERAPY; NEOADJUVANT PALBOCICLIB; MOLECULAR PORTRAITS; INTRINSIC SUBTYPES; OPEN-LABEL; MULTICENTER; RESISTANCE; SIGNATURE;

D O I：

10.1007/s12254-023-00878-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice.

引用

页码：135 / 144

页数：10

共 50 条

[1] Position paper on CDK4/6 inhibitors in early breast cancer
Michael Gnant
Christian F. Singer
Gabriel Rinnerthaler
Georg Pfeiler
Daniel Egle
Marija Balic
Rupert Bartsch
memo - Magazine of European Medical Oncology, 2023, 16 : 135 - 144
[2] The role of CDK4/6 inhibitors in early breast cancer
Gil-Gil, Miguel
Alba, Emilio
Gavila, Joaquin
de la Haba-Rodriguez, Juan
Ciruelos, Eva
Tolosa, Pablo
Candini, Daniele
Llombart-Cussac, Antonio
BREAST, 2021, 58 : 160 - 169
[3] The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, Conleth G.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
[4] CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Mohammed, Amrallah A.
Rashied, Hanaa
Elsayed, Fifi Mostafa
ONCOLOGY REVIEWS, 2019, 13 (02) : 125 - 133
[5] Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, Sibylle
Furlanetto, Jenny
BREAST, 2022, 62 : S70 - S79
[6] CDK4/6 inhibitors in breast cancer
Dukelow, Tim
Kishan, Divya
Khasraw, Mustafa
Murphy, Conleth G.
ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
[7] Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
Gnant, Michael
Balic, Marija
Singer, Christian F.
Rinnerthaler, Gabriel
Pfeiler, Georg
Suppan, Christoph
Gruenberger, Birgit
Strasser-Weippl, Kathrin
Castagnaviz, Vanessa
Heibl, Sonja
Bartsch, Rupert
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2025, 18 (01) : 4 - 18
[8] The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, Ines
Abreu, Catarina
Costa, Luis
Casimiro, Sandra
CANCERS, 2023, 15 (19)
[9] The Role of CDK4/6 Inhibitors in Breast Cancer
Conleth G. Murphy
Current Treatment Options in Oncology, 2019, 20
[10] CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety
Wekking, Demi
Lambertini, Matteo
Dessi, Mariele
Denaro, Nerina
Bardanzellu, Fabio
Garrone, Ornella
Scartozzi, Mario
Solinas, Cinzia
SEMINARS IN ONCOLOGY, 2023, 50 (06) : 131 - 139

← 1 2 3 4 5 →